Search research articles
Contact Us
Filters
Showing results (11-20 of 22) with videos related to
Page
of 3
Sort By:
BMC Ear, Nose, and Throat Disorders
|
January 13, 2011
A randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of neramexane in patients with moderate to severe subjective tinnitus
Markus Suckfüll, Michael Althaus, Barbara Ellers-Lenz, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|
December 20, 2022
Fosgonimeton, a Novel Positive Modulator of the HGF/MET System, Promotes Neurotrophic and Procognitive Effects in Models of Dementia
Jewel L Johnston, Sherif M Reda, Sharay E Setti, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|
April 10, 2024
Fosgonimeton attenuates amyloid-beta toxicity in preclinical models of Alzheimer's disease
Sherif M Reda, Sharay E Setti, Andrée-Anne Berthiaume, et al.
Journal of Alzheimer'S Disease Reports
|
December 15, 2025
Fosgonimeton in mild-to-moderate Alzheimer's disease
Anton P Porsteinsson, Marwan Sabbagh, Pierre N Tariot, et al.
Frontiers in Neuroscience
|
February 23, 2024
ATH-1105, a small-molecule positive modulator of the neurotrophic HGF system, is neuroprotective, preserves neuromotor function, and extends survival in preclinical models of ALS
Andrée-Anne Berthiaume, Sherif M Reda, Kayla N Kleist, et al.
International Psychogeriatrics
|
April 25, 2025
Mapping of validated apathy scales onto the apathy diagnostic criteria for neurocognitive disorders
K Sankhe, K K Bawa, D S Miller, et al.
Alzheimer'S & Dementia (New York, N. Y.)
|
January 3, 2025
Application of the revised criteria for diagnosis and staging of Alzheimer's disease: Drug development and clinical practice
Clifford R Jack, Ana Graf, Samantha C Burnham, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists
|
August 21, 2018
Is it time to revise the diagnostic criteria for apathy in brain disorders? The 2018 international consensus group
P Robert, K L Lanctôt, L Agüera-Ortiz, et al.
Lancet (London, England)
|
November 20, 2016
Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial
Serge Gauthier, Howard H Feldman, Lon S Schneider, et al.
Journal of Alzheimer'S Disease : JAD
|
April 14, 2020
Concentration-Dependent Activity of Hydromethylthionine on Clinical Decline and Brain Atrophy in a Randomized Controlled Trial in Behavioral Variant Frontotemporal Dementia
Helen Shiells, Bjoern O Schelter, Peter Bentham, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 22) with videos related to
Sort By:
Page
of 3
BMC Ear, Nose, and Throat Disorders
|
January 13, 2011
A randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of neramexane in patients with moderate to severe subjective tinnitus
Markus Suckfüll, Michael Althaus, Barbara Ellers-Lenz, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|
December 20, 2022
Fosgonimeton, a Novel Positive Modulator of the HGF/MET System, Promotes Neurotrophic and Procognitive Effects in Models of Dementia
Jewel L Johnston, Sherif M Reda, Sharay E Setti, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|
April 10, 2024
Fosgonimeton attenuates amyloid-beta toxicity in preclinical models of Alzheimer's disease
Sherif M Reda, Sharay E Setti, Andrée-Anne Berthiaume, et al.
Journal of Alzheimer'S Disease Reports
|
December 15, 2025
Fosgonimeton in mild-to-moderate Alzheimer's disease
Anton P Porsteinsson, Marwan Sabbagh, Pierre N Tariot, et al.
Frontiers in Neuroscience
|
February 23, 2024
ATH-1105, a small-molecule positive modulator of the neurotrophic HGF system, is neuroprotective, preserves neuromotor function, and extends survival in preclinical models of ALS
Andrée-Anne Berthiaume, Sherif M Reda, Kayla N Kleist, et al.
International Psychogeriatrics
|
April 25, 2025
Mapping of validated apathy scales onto the apathy diagnostic criteria for neurocognitive disorders
K Sankhe, K K Bawa, D S Miller, et al.
Alzheimer'S & Dementia (New York, N. Y.)
|
January 3, 2025
Application of the revised criteria for diagnosis and staging of Alzheimer's disease: Drug development and clinical practice
Clifford R Jack, Ana Graf, Samantha C Burnham, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists
|
August 21, 2018
Is it time to revise the diagnostic criteria for apathy in brain disorders? The 2018 international consensus group
P Robert, K L Lanctôt, L Agüera-Ortiz, et al.
Lancet (London, England)
|
November 20, 2016
Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial
Serge Gauthier, Howard H Feldman, Lon S Schneider, et al.
Journal of Alzheimer'S Disease : JAD
|
April 14, 2020
Concentration-Dependent Activity of Hydromethylthionine on Clinical Decline and Brain Atrophy in a Randomized Controlled Trial in Behavioral Variant Frontotemporal Dementia
Helen Shiells, Bjoern O Schelter, Peter Bentham, et al.
Page
of 3